Suppr超能文献

自然杀伤细胞在脐血移植中的作用及其通过杀伤细胞免疫球蛋白样受体的缺失配体效应得到增强。

Role of NK cells in cord blood transplantation and their enhancement by the missing ligand effect of the killer-immunoglobulin like receptor.

作者信息

Yokoyama Hisayuki

机构信息

Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan.

出版信息

Front Genet. 2022 Oct 18;13:1041468. doi: 10.3389/fgene.2022.1041468. eCollection 2022.

Abstract

Natural killer (NK) cells are the first lymphocytes reconstituted after allogenic hematopoietic stem cell transplantation (HSCT). Especially, in cord blood transplantation (CBT), the increase in the number of NK cells is sustained for a long period. Although there are conflicting results, many studies show that early reconstitution of NK cells is associated with favorable CBT outcomes, suggesting that maximizing NK cell functions could improve the CBT outcome. Killer immunoglobulin-like receptors (KIRs) include inhibitory and stimulatory receptors, which can regulate NK-cell activity. Because some of the KIRs have HLA class I as their ligand, the KIR-ligand interaction on NK cells can be lost in some cases of CBT, which results in the activation of NK cells and alters HSCT outcome. Thus, effects of KIR-ligand mismatch under various conditions have been widely examined; however, the results have been controversial. Among such studies, those using the largest number of CBTs showed that HLA-C2 (KIR2DL1-ligand) mismatches have a favorable effect on the relapse rate and overall survival only when the CBT used methotrexate for graft-versus-host disease prophylaxis. Another study suggested that KIR-ligand mismatch is involved in reducing the relapse of acute myeloid leukemia, mediated by reactivation of cytomegalovirus. These results indicate that activation of NK cells by KIR-ligand mismatch may have favorable effects on CBT outcomes and could help enhance the NK-cell function.

摘要

自然杀伤(NK)细胞是同种异体造血干细胞移植(HSCT)后最早重建的淋巴细胞。特别是在脐带血移植(CBT)中,NK细胞数量的增加会持续很长一段时间。尽管存在相互矛盾的结果,但许多研究表明,NK细胞的早期重建与CBT的良好结果相关,这表明最大化NK细胞功能可以改善CBT结果。杀伤细胞免疫球蛋白样受体(KIR)包括抑制性和刺激性受体,它们可以调节NK细胞的活性。由于一些KIR以I类人类白细胞抗原(HLA)作为其配体,在某些CBT病例中,NK细胞上的KIR-配体相互作用可能会丧失,从而导致NK细胞活化并改变HSCT结果。因此,人们广泛研究了各种条件下KIR-配体错配的影响;然而,结果一直存在争议。在这些研究中,那些使用最多CBT病例的研究表明,只有当CBT使用甲氨蝶呤预防移植物抗宿主病时,HLA-C2(KIR2DL1-配体)错配才对复发率和总生存率有有利影响。另一项研究表明,KIR-配体错配参与降低急性髓细胞白血病的复发,这是由巨细胞病毒的重新激活介导的。这些结果表明,KIR-配体错配激活NK细胞可能对CBT结果有有利影响,并有助于增强NK细胞功能。

相似文献

3
Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch.
Bone Marrow Transplant. 2022 Jul;57(7):1171-1179. doi: 10.1038/s41409-022-01700-y. Epub 2022 May 10.
4
Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
Bone Marrow Transplant. 2021 Dec;56(12):3059-3067. doi: 10.1038/s41409-021-01469-6. Epub 2021 Sep 24.
5
Impact of KIR-ligand mismatch on pediatric T-cell acute lymphoblastic leukemia in unrelated cord blood transplantation.
Transplant Cell Ther. 2022 Sep;28(9):598.e1-598.e8. doi: 10.1016/j.jtct.2022.05.037. Epub 2022 Jun 1.
6
9
Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Better Outcome after Umbilical Cord Blood Transplantation.
Front Immunol. 2017 Jul 13;8:810. doi: 10.3389/fimmu.2017.00810. eCollection 2017.

引用本文的文献

本文引用的文献

1
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
Int J Hematol. 2022 Sep;116(3):330-340. doi: 10.1007/s12185-022-03416-7. Epub 2022 Jul 16.
3
Improved outcomes of single-unit cord blood transplantation for acute myeloid leukemia by killer immunoglobulin-like receptor 2DL1-ligand mismatch.
Bone Marrow Transplant. 2022 Jul;57(7):1171-1179. doi: 10.1038/s41409-022-01700-y. Epub 2022 May 10.
5
KIR in Allogeneic Hematopoietic Stem Cell Transplantation: Need for a Unified Paradigm for Donor Selection.
Front Immunol. 2022 Feb 15;13:821533. doi: 10.3389/fimmu.2022.821533. eCollection 2022.
6
Altered effect of killer immunoglobulin-like receptor-ligand mismatch by graft versus host disease prophylaxis in cord blood transplantation.
Bone Marrow Transplant. 2021 Dec;56(12):3059-3067. doi: 10.1038/s41409-021-01469-6. Epub 2021 Sep 24.
8
Bispecific Antibodies: From Research to Clinical Application.
Front Immunol. 2021 May 5;12:626616. doi: 10.3389/fimmu.2021.626616. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验